Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma

The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowing advanced practitioners to provide multiple myeloma patients a...

Descripción completa

Detalles Bibliográficos
Autor principal: Ramirez, Krista G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040877/
https://www.ncbi.nlm.nih.gov/pubmed/30018846
_version_ 1783338904358748160
author Ramirez, Krista G.
author_facet Ramirez, Krista G.
author_sort Ramirez, Krista G.
collection PubMed
description The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowing advanced practitioners to provide multiple myeloma patients an exclusively oral triplet therapy.
format Online
Article
Text
id pubmed-6040877
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-60408772018-07-17 Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma Ramirez, Krista G. J Adv Pract Oncol Review Article The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowing advanced practitioners to provide multiple myeloma patients an exclusively oral triplet therapy. Harborside Press 2017 2017-05-01 /pmc/articles/PMC6040877/ /pubmed/30018846 Text en Copyright © 2017, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Ramirez, Krista G.
Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
title Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
title_full Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
title_fullStr Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
title_full_unstemmed Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
title_short Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
title_sort ixazomib: an oral proteasome inhibitor for the treatment of multiple myeloma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040877/
https://www.ncbi.nlm.nih.gov/pubmed/30018846
work_keys_str_mv AT ramirezkristag ixazomibanoralproteasomeinhibitorforthetreatmentofmultiplemyeloma

Ejemplares similares